Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 1.00 |
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.81 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.81 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.81 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.81 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.81 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.81 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.81 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | NTSR1 | P30989 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.81 |
| ▸ | ABL1 | P00519 | 2/20 | 0.81 |
| ▸ | HTR1A | P08908 | 2/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL162935 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL15939735 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL18496409 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL28204502 | 0.99 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3660939 | 0.99 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL16051185 | 0.97 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3664023 | 0.97 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Cm-4307 SCHEMBL14673524 | 0.95 | KDR (0.90) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL19322 | 0.93 | KDR (0.87) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL18264082 | 0.93 | KDR (0.86) | KDRAURKBNTSR1MC4RPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712965-A2 | BENZIMIDAZOLE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Springworks Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4713313-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Springworks Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260076954-A1 | COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELLS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-03-19 | — | — | US | disclosed |
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12544368-B2 | Compositions and methods for reducing cancer stem cells | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-02-10 | — | — | US | disclosed |
| US-12516064-B2 | Tetrahydropyridopyrimidines and related analogs for inhibiting YAP/TAZ-TEAD | SpringWorks Therapeutics Inc. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12378202-B2 | Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250115574-A1 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | VIB VZW (BE) | 2025-04-10 | — | — | US | disclosed |
| EP-4482826-A1 | DIHYDROQUINAZOLINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | The Katholieke Universiteit Leuven (BE) | 2025-01-01 | — | — | EP | disclosed |
| US-20240417398-A1 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. | 2024-12-19 | — | — | US | disclosed |
| WO-2023122782-A2 | INDOLES, INDAZOLES, AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122784-A2 | SPIROS AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122783-A2 | TETRAHYDROPYRAZOLOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20230202985-A1 | Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD | CISTIM LEUVEN VZW (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2023122781-A2 | TETRAHYDROBENZOAZEPINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122780-A2 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20230203035-A1 | Spiros and Related Analogs for Inhibiting YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4164664-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS USING OSCILLOSPIRACEAE MICROBIAL EXTRACELLULAR VESICLES | Evelo Biosciences, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4149557-A1 | NUCLEIC ACID LIGAND CONJUGATES AND USE THEREOF FOR DELIVERY TO CELLS | The University of North Carolina at Chapel Hill (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220280506-A1 | OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHODS OF USE THEREOF, AND PREPARATION METHODS THEREOF | ALLGENESIS BIOTHERAPEUTICS INC (TW) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202985-A1 | Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD3 | KDR 3729/4885RAF1 1293/4885BRAF 1323/4885 |
| US-20220280506-A1 | OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHODS OF USE THEREOF, AND PREPARATION METHODS THEREOF | TYRO3, JAK1, AXL | KDR 16/4885RAF1 171/4885BRAF 52/4885 |
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | KDR 2676/4885RAF1 705/4885BRAF 545/4885 |
| US-12544368-B2 | Compositions and methods for reducing cancer stem cells | MCL1, BCL9, MYADM | KDR 2495/4885RAF1 3025/4885BRAF 2234/4885 |
| US-12378202-B2 | Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD4 | KDR 3078/4885RAF1 1214/4885BRAF 1387/4885 |
| US-20240417398-A1 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | KDR 3026/4885RAF1 2003/4885BRAF 2032/4885 |
| US-20230203035-A1 | Spiros and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | KDR 3024/4885RAF1 544/4885BRAF 825/4885 |
| US-20260076954-A1 | COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELLS | MCL1, FLT3, MYADM | KDR 1002/4885RAF1 3261/4885BRAF 1981/4885 |
| US-20250115574-A1 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | KDR 3308/4885RAF1 1056/4885BRAF 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.